Should we treat high-normal blood pressure?

Journal of Hypertension

Volumn 20, Issue 10, 2002, Pages 2057-2062

  Rowland Yeo, Karen ^a   Yeo, Wilfred W ^a  

^a ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

Antihypertensive treatment; Cardiovascular risk; High normal blood pressure

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; POPULATION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT PLANNING; UNITED KINGDOM; ADOLESCENT; AGE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DIASTOLE; DRUG EFFECT; HOSPITALIZATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTION AND FORECASTING; PREVALENCE; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SYSTOLE; TREATMENT OUTCOME;

ANTIHYPERTENSIVE AGENT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; DIASTOLE; ENGLAND; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PREVALENCE; RISK FACTORS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SYSTOLE; TREATMENT OUTCOME;

EID: 0036807503     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200210000-00026     Document Type: Article

References (18)

1. British Heart Foundation Health Promotion Research Group. European Cardiovascular Disease Statistics. London: British Heart Foundation; 2000.
2. Haq IU, Jackson PR, Yeo WW, Ramsey LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 1995; 346:1467-1471.
3. Wallis EJ, Ramsay LE, UI Haq I, Ghahramani P, Jackson PR, Rowland Yeo K, et al. Coronary and cardiovascular risk estimation for primary prevention: Validation of a new Sheffield table in the 1995 Scottish Health Survey population. BMJ 2000; 320:671-676.
4. Wood D, Durrington P, Poulter N, McInnes G, Rees A, Wray R. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80 (suppl 2):S1-S29.
5. NSF for coronary heart disease. Modern Standards and Service Models, 2000. Department of Health, London: Stationery Office; 2000.
6. Heart Protection Study. http//www.hpsinfo.org
7. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or ischaemic attack. Lancet 2001; 358:1033-1041.
8. Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, et al. British hypertension society guidelines for hypertension management 1999: Summary. BMJ 1999; 319:630-635.
9. Vasan RS, Larson MG, Leip EP, Evans JC, O'Donnell CJ, Kannel WB, et al. Impact of high-normal blood pressure on the risk of cardiovascular disease. N Engl J Med 2001; 345:1291-1297.
10. Vasan RS, Larson MG, Leip EP, Kannel WB, Levy D. Assessment of progression to hypertension in non-hypertensive participants in the Framingham heart study: A cohort study. Lancet 2001; 358: 1682-1686.
11. Erens B, Primatesta P, eds. Health Survey for England. Cardiovascular Disease '98. Vol 1. Findings. London: Stationery Office; 1999.
12. Primatesta P, Poulter NR. Lipid concentrations and the use of lipid-lowering drugs: Evidence from a national cross sectional survey. BMJ 2000; 321:1322-1325.
13. Guidelines Subcommittee. 1999 World Health Organisation-International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17:127-144.
14. Joint National Committee. The sixth report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157:2413-2446.
15. Rowland Yeo K, Yeo WW. Lipid-lowering in patients with diabetes mellitus: What CHD risk threshold should be used? Heart 2002; 87:423-427.
16. Anderson KM, Odel PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121:293-298.
17. The HOPE Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 2000; 342:145-153.
18. O'Brien E, Waeber B, Parati G, Staessen J, Myers MG, on behalf of the European Society of Hypertension Working Group on Blood Pressure Monitoring. Blood pressure measuring devices: Recommendations of the European Society of Hypertension. BMJ 2001; 322:531-536.